Ameriprise Financial Inc. Acquires 592,575 Shares of CVS Health Corporation $CVS

Ameriprise Financial Inc. grew its holdings in shares of CVS Health Corporation (NYSE:CVS) by 7.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,448,420 shares of the pharmacy operator’s stock after buying an additional 592,575 shares during the period. Ameriprise Financial Inc. owned approximately 0.67% of CVS Health worth $636,955,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of CVS Health by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock valued at $8,305,132,000 after buying an additional 2,063,737 shares during the period. Capital World Investors grew its stake in CVS Health by 2.1% in the third quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock valued at $5,155,380,000 after acquiring an additional 1,419,575 shares during the period. State Street Corp increased its holdings in shares of CVS Health by 1.4% during the second quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock valued at $4,055,237,000 after acquiring an additional 800,414 shares in the last quarter. Capital International Investors raised its position in shares of CVS Health by 1.1% during the third quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock worth $2,012,347,000 after purchasing an additional 302,499 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of CVS Health by 3.2% in the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock worth $1,831,454,000 after purchasing an additional 760,579 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

CVS Health Price Performance

Shares of NYSE CVS opened at $76.14 on Monday. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15. The company has a market capitalization of $96.87 billion, a PE ratio of 55.17, a PEG ratio of 0.79 and a beta of 0.49. The stock’s 50 day moving average price is $78.17 and its 200-day moving average price is $77.83. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. During the same quarter last year, the company posted $1.19 earnings per share. The firm’s quarterly revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio is presently 192.75%.

Wall Street Analyst Weigh In

A number of analysts have commented on CVS shares. Morgan Stanley boosted their price target on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. JPMorgan Chase & Co. lifted their price objective on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. The Goldman Sachs Group boosted their target price on shares of CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a research report on Thursday, February 12th. Leerink Partners reaffirmed an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Finally, Argus cut their price target on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, January 28th. Twenty investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $95.05.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.